Tumour dormancy and clinical implications in breast cancer

被引:28
作者
Gelao, L. [1 ]
Criscitiello, C. [1 ]
Fumagalli, L. [1 ]
Locatelli, M. [1 ]
Manunta, S. [1 ]
Esposito, A. [1 ]
Minchella, I. [1 ]
Goldhirsch, A. [1 ]
Curigliano, G. [1 ]
机构
[1] European Inst Oncol, Early Drug Dev Innovat Therapy Div, Milan, Italy
关键词
tumor dormancy; breast cancers; angiogenesis; microenvironment; immune surveillance;
D O I
10.3332/ecancer.2013.320
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of adjuvant therapy in breast cancer is to reduce the risk of recurrence. Some patients develop metastases many years after apparently successful treatment of their primary cancer. Tumour dormancy may explain the long time between initial diagnosis and treatment of cancer, and occurrence of relapse. The regulation of the switch from clinical dormancy to cancer regrowth in locoregional and distant sites is poorly understood. In this review, we report some data supporting the existence of various factors that may explain cancer dormancy including genetic and epigenetic changes, angiogenic switch, microenvironment, and immunosurveillance. A better definition and understanding of these factors should allow the identification of patients at high risk of relapse and to develop new therapeutic strategies in order to improve prognosis.
引用
收藏
页数:15
相关论文
共 75 条
[11]   Extrinsic regulators of epithelial tumor progression: metalloproteinases [J].
Bergers, G ;
Coussens, LM .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2000, 10 (01) :120-127
[12]  
Bragado Paloma, 2012, Recent Results Cancer Res, V195, P25, DOI 10.1007/978-3-642-28160-0_3
[13]   Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases [J].
Carlsson, Anders ;
Wingren, Christer ;
Kristensson, Malin ;
Rose, Carsten ;
Ferno, Marten ;
Olsson, Hakan ;
Jernstrom, Helena ;
Ek, Sara ;
Gustavsson, Elin ;
Ingvar, Christian ;
Ohlsson, Mattias ;
Peterson, Carsten ;
Borrebaeck, Carl A. K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (34) :14252-14257
[14]   Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [J].
Carmeliet, P ;
Dor, Y ;
Herbert, JM ;
Fukumura, D ;
Brusselmans, K ;
Dewerchin, M ;
Neeman, M ;
Bono, F ;
Abramovitch, R ;
Maxwell, P ;
Koch, CJ ;
Ratcliffe, P ;
Moons, L ;
Jain, RK ;
Collen, D ;
Keshet, E .
NATURE, 1998, 394 (6692) :485-490
[15]   Platelet-associated PF-4 as a biomarker of early tumor growth [J].
Cervi, David ;
Yip, Tai-Tung ;
Bhattacharya, Nandita ;
Podust, Vladimir N. ;
Peterson, Jon ;
Abou-Slaybi, Abdo ;
Naumov, George N. ;
Bender, Elise ;
Almog, Nava ;
Italiano, Joseph E., Jr. ;
Folkman, Judah ;
Klement, Giannoula L. .
BLOOD, 2008, 111 (03) :1201-1207
[16]   Breast-Cancer Adjuvant Therapy with Zoledronic Acid [J].
Coleman, Robert E. ;
Marshall, Helen ;
Cameron, David ;
Dodwell, David ;
Burkinshaw, Roger ;
Keane, Maccon ;
Gil, Miguel ;
Houston, Stephen J. ;
Grieve, Robert J. ;
Barrett-Lee, Peter J. ;
Ritchie, Diana ;
Pugh, Julia ;
Gaunt, Claire ;
Rea, Una ;
Peterson, Jennifer ;
Davies, Claire ;
Hiley, Victoria ;
Gregory, Walter ;
Bell, Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15) :1396-1405
[17]   Anticancer evidence for zoledronic acid across the cancer continuum [J].
Costa, Luis ;
Harper, Peter ;
Coleman, Robert E. ;
Lipton, Allan .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 77 :S31-S37
[18]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998
[19]   The three Es of cancer immunoediting [J].
Dunn, GP ;
Old, LJ ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :329-360
[20]   Migration rules: tumours are conglomerates of self-metastases [J].
Enderling, H. ;
Hlatky, L. ;
Hahnfeldt, P. .
BRITISH JOURNAL OF CANCER, 2009, 100 (12) :1917-1925